RxDoctor Payments Data

David O Neil, MD

Cardiovascular Disease · Philadelphia, PANPI 1831158930

Payments from drug & device makers

$1,364in general payments, 2019–2025

Across 62 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$315
  • Novo Nordisk$230
  • Philips North America LLC$132
  • Amgen$121
  • GE HealthCare$119
  • Boston Scientific$118
  • plus $331 from 11 others

What the payments were for

  • Food & beverage$1,34298%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,364 in reported general payments places this provider in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$179,802
Medicare patients
1,297
Services billed
3,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban298$406,177
OzempicSemaglutide39$82,610
Repatha SureclickEvolocumab56$79,976
EntrestoSacubitril/Valsartan66$71,884
XareltoRivaroxaban57$65,147
Praluent PenAlirocumab62$58,183
FarxigaDapagliflozin Propanediol32$37,213
JardianceEmpagliflozin24$35,353
NexletolBempedoic Acid29$15,375
Metoprolol Succinate520$8,827
Candesartan Cilexetil68$7,901
Ezetimibe275$7,805
VascepaIcosapent Ethyl11$7,757
Rosuvastatin Calcium411$7,387
DapagliflozinDapagliflozin Propanediol11$6,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$406,177298 claims
Novo NordiskOzempic$230$82,61039 claims
NovartisEntresto$59$71,88466 claims
Johnson & JohnsonXarelto$14$65,14757 claims
AstraZenecaFarxiga$12$37,21332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →